Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research LLP

      Feb 10, 2026, 17:31 ET

      Share this article

      Share this article


      The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical trials such as vepdegestrant (Arvinas and Pfizer), luxdegalutamide (Arvinas and Novartis), ASP3082 (Astellas Pharma), DT2216 (Dialectic Therapeutics), and others, along with increasing applicability in neurodegenerative and inflammatory diseases, are further fueling sustained R&D investment.

      LAS VEGAS, Feb. 10, 2026 /PRNewswire/ -- DelveInsight's PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging PROTAC, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

      Key Takeaways from the PROTAC Market Report

      • The total market size of PROTAC in the leading markets is expected to surge significantly by 2034.
      • The report provides the total potential number of patients in the indications, such as HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others.
      • Approximately 85% of patients diagnosed with metastatic breast cancer have had an early-stage breast cancer diagnosis. However, most patients with early-stage breast cancer do not go on to develop metastatic disease.
      • Leading PROTAC companies, such as Arvinas (NASDAQ: ARVN), Pfizer (NYSE: PFE), Novartis (SWX: NOVN), Astellas Pharma (TYO: 4503), Dialectic Therapeutics, and others, are developing novel PROTAC that can be available in the PROTAC market in the coming years. 
      • Some of the key PROTACs in clinical trials include Vepdegestrant, Luxdegalutamide, ASP3082, DT2216, and others.

      Discover PROTAC market CAGR and revenue projections @ https://www.delveinsight.com/sample-request/protac-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

      Key Factors Driving the PROTAC Market 

      • High Therapeutic Potential and Mechanism of Action: PROTACs offer a novel mechanism that selectively degrades disease-causing proteins rather than simply inhibiting them. This expands therapeutic possibilities, especially for targets previously considered "undruggable", boosting industry and investor interest.
      • Rising Prevalence of Target Diseases: The increasing global burden of complex diseases, such as breast cancer, TNBC, mCRPC, colorectal cancer, NSCLC, and others, fuels the demand for innovative treatment options. PROTACs' ability to target pathogenic proteins drives research and clinical investment.
      • Next-Generation AR Degradation in Mutant Androgen Receptor–Driven Prostate Cancer: Prostate cancer is traditionally treated with anti-androgen medications. However, PROTACs such as ARV-766 are thought to be effective in patients with AR that has mutated, particularly through a resistance mechanism such as L702H. ARV-766 has a superior and expanded efficacy profile and an improved tolerability profile compared with bavdegalutamide.
      • Pharmaceutical Partnerships and Licensing Landscape: Opportunities for clinical collaboration and licensing with large pharmaceutical companies are presented here. Novartis paid USD 150 million up front, primarily for the rights to Arvinas's androgen receptor degrader ARV-766, thereby providing the company a second endorsement of its degradation strategy. It is important to note that Pfizer is already a partner with Arvinas for the PROTAC vepdegestrant.
      • Emerging PROTAC Drugs in Development: Some of the potential drugs in the pipeline include vepdegestrant (Arvinas and Pfizer), luxdegalutamide (Arvinas and Novartis), ASP3082 (Astellas Pharma), DT2216 (Dialectic Therapeutics), and others.

      PROTAC Market Analysis

      • Targeted Protein Degradation (TPD) is an emerging therapeutic modality with the potential to target disease-causing proteins that have historically been difficult to reach with conventional small molecules.
      • PROTACs are a key class of targeted protein degradation technologies, and over the past 20 years, the concept of harnessing the ubiquitin–proteasome system has evolved from academic research into active industry-led drug development.
      • Nearly 90 protein degradation–based leads are currently under evaluation, with close to 20% of pipeline candidates in clinical development and the remainder in preclinical or discovery stages.
      • PROTACs account for more than 30% of all protein degradation pipeline drugs, underscoring their growing prominence in this therapeutic space.
      • The PROTAC market is expected to expand significantly in the coming years, driven by the rising number of PROTAC-designed molecules entering clinical trials, despite the absence of any approved therapies to date.
      • The first PROTAC molecule, ARV-110, entered clinical testing in 2019, marking a major milestone for the modality.
      • In 2020, early clinical data provided the first proof-of-concept for PROTACs against well-established cancer targets, including the estrogen receptor (ER) and androgen receptor (AR).
      • Pfizer, in collaboration with Arvinas, is currently evaluating vepdegestrant in clinical trials as both a monotherapy and in combination regimens for ER+/HER2- breast cancer and other indications.
      • Several major players, including Arvinas and Pfizer (Vepdegestrant), Arvinas and Novartis (Luxdegalutamide), Astellas Pharma (ASP3082), Dialectic Therapeutics (DT2216), and others, are advancing PROTAC-based therapies across multiple oncology indications such as ER+/HER2- breast cancer and metastatic prostate cancer.
      • Overall, PROTACs represent an exciting and rapidly maturing class of therapeutic agents, with ongoing and future studies expected to clarify their clinical role in cancer and other diseases.

      Learn more about PROTACs in oncology vs other indications @ PROTAC Analysis

      PROTAC Competitive Landscape

      Emerging players such as Arvinas and Pfizer (Vepdegestrant), Arvinas and Novartis (Luxdegalutamide), Astellas Pharma (ASP3082), Dialectic Therapeutics (DT2216), and others are evaluating drugs in clinical trials.

      Arvinas and Pfizer's Vepdegestrant is an investigational, orally bioavailable PROTAC-based protein degrader engineered to selectively eliminate the estrogen receptor and is being developed for the treatment of ER+/HER2– breast cancer. In July 2021, Arvinas entered into a global partnership with Pfizer to jointly develop and commercialize vepdegestrant, with the two companies sharing worldwide development costs, commercialization expenses, and profits.

      Arvinas and Novartis' ARV-766 is an investigational, orally bioavailable PROTAC protein degrader designed to selectively target and degrade the androgen receptor. In preclinical studies, ARV-766 has shown activity across models expressing wild-type androgen receptor as well as tumors harboring androgen receptor mutations or amplification, key mechanisms associated with resistance to existing androgen receptor–directed therapies. ARV-766 is currently being evaluated in a Phase II clinical trial for metastatic prostate cancer. In April 2024, Arvinas entered into an exclusive global licensing agreement with Novartis for the development and commercialization of ARV-766. The transaction also included an asset purchase agreement under which Novartis acquired Arvinas' preclinical AR-V7 program.

      Astellas Pharma's ASP3082 is a PROTAC molecule that selectively degrades the KRAS G12D protein and represents the first targeted protein degrader to advance into clinical development for this target. It has the potential to become a first-in-class therapy for solid tumors driven by KRAS G12D mutations. A Phase I clinical trial is currently ongoing in patients with KRAS G12D–mutant solid tumors, with proof-of-concept data expected in the first half of calendar year 2025. The company is preparing to advance the program into registration trials.

      The anticipated launch of these emerging therapies are poised to transform the PROTAC market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the PROTAC market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      To know more about pipeline PROTAC drugs and commercial potential, visit @ PROTAC Treatment 

      Recent Developments in the PROTAC Market

      • In November 2025, Arvinas presented multiple abstracts on vepdegestrant at the San Antonio Breast Cancer Symposium (SABCS).
      • In October 2025, Arvinas announced new patient-reported outcomes data from the Phase III VERITAC-2 clinical trial evaluating vepdegestrant, which are being presented in a mini oral session at the 2025 European Society for Medical Oncology (ESMO) Congress.
      • In March 2025, Arvinas and Pfizer announced positive topline results from the Phase III VERITAC-2 trial, which met its primary endpoint in the ESR1m population, showing a significant improvement in progression-free survival (PFS) compared to fulvestrant, exceeding the pre-specified target Hazard Ratio (HR) of 0.60. However, the trial did not reach statistical significance in the intent-to-treat (ITT) population. 

      What are PROTACs?

      PROTACs (PROteolysis TArgeting Chimeras) are an emerging class of therapeutic molecules designed to selectively degrade disease-causing proteins rather than merely inhibiting them. They are heterobifunctional compounds that simultaneously bind a target protein and an E3 ubiquitin ligase, bringing the two into close proximity and triggering ubiquitination of the target protein. This process marks the protein for destruction by the cell's natural proteasome system. By eliminating the protein entirely, PROTACs can achieve deeper and more sustained biological effects, overcome resistance seen with traditional inhibitors, and enable targeting of previously "undruggable" proteins. As a result, PROTAC technology is gaining significant traction across oncology, immunology, and other therapeutic areas.

      PROTAC Epidemiology Segmentation

      The PROTAC market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. The PROTAC target patient pool is segmented into:

      • Total Cases of Selected Indications for PROTAC
      • Total Eligible Patient Pool for PROTAC in Selected Indications
      • Total Treated Cases in Selected Indications for PROTAC

      PROTAC Report Metrics

      Details

      Study Period

      2020–2034

      PROTAC Report Coverage

      7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

      Key Indications Covered in the Report

      HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), and others 

      PROTAC Target Patient Pool Segmentation

      Total Cases of Selected Indications for PROTAC, Total Eligible Patient Pool for PROTAC in Selected Indications, and Total Treated Cases in Selected Indications for PROTAC

      Key PROTAC Companies

      Arvinas (NASDAQ: ARVN), Pfizer (NYSE: PFE), Novartis (SWX: NOVN), Astellas Pharma (TYO: 4503), Dialectic Therapeutics, and others

      Key PROTACs

      Vepdegestrant, Luxdegalutamide, ASP3082, DT2216, and others

      Scope of the PROTAC Market Report

      • PROTAC Therapeutic Assessment: PROTAC' current marketed and emerging therapies
      • PROTAC Market Dynamics: Conjoint Analysis of Emerging PROTAC Drugs
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, PROTAC Market Access and Reimbursement

      Discover emerging technologies for PROTAC design @ PROTAC Clinical Trials

      Table of Contents

      1

      PROTAC Market Key Insights

      2

      PROTAC Market Report Introduction

      3

      Executive Summary

      4

      Key Events

      5

      Epidemiology and Market Forecast Methodology

      6

      PROTAC Therapies Market Overview at a Glance

      6.1

      Clinical Landscape (Analysis by Molecule Type, Phase, and Route of Administration [RoA])

      6.2

      Market Share (%) Distribution by Indications of PROTAC Therapies in 2028

      6.3

      Market Share (%) Distribution by Therapies of PROTAC Therapies in 2036

      7

      Background and Overview

      8

      Treatment Guidelines

      9

      Epidemiology and Patient Population

      9.1

      Key Findings

      9.2

      Assumptions and Rationale: 7MM

      9.3

      Epidemiology Scenario in the 7MM

      9.3.1

      Total Cases of Selected Indications for PROTACs in the 7MM

      9.3.2

      Total Eligible Patient Pool for PROTACs in Selected Indications in the 7MM

      9.3.3

      Total Treated Cases in Selected Indications for PROTACs in the 7MM

      10

      Emerging PROTAC Drugs

      10.1

      Key Cross Competition

      10.2

      Vepdegestrant (ARV-471): Arvinas and Pfizer

      10.2.1

      Product Description

      10.2.2

      Other Development Activities

      10.2.3

      Clinical Development

      10.2.3.1

      Clinical Trial Information

      10.2.4

      Safety and Efficacy

      10.2.5

      Analyst's Views

      10.3

      Luxdegalutamide (ARV-766): Arvinas and Novartis

      List to be continued…..

      11

      PROTAC Therapies Market: Seven Major Market Analysis

      11.1

      Key Findings

      11.2

      PROTAC Market Outlook

      11.3

      Conjoint Analysis

      11.4

      Key PROTAC Market Forecast Assumptions

      11.5

      Total PROTAC Market Size by Country in the 7MM

      11.6

      Total PROTAC Market Size by Indications in the 7MM

      11.7

      Total PROTAC Market Size by Therapies in the 7MM

      11.8

      The United States PROTAC Market Size

      11.8.1

      Total PROTAC Market Size by Indications in the United States

      11.8.2

      Total PROTAC Market Size by Therapies in the United States

      11.9

      EU4 and the UK PROTAC Market Size

      11.1

      Japan PROTAC Market Size

      12

      PROTAC Market Unmet Needs

      13

      PROTAC Market SWOT Analysis

      14

      KOL Views on PROTAC 

      15

      PROTAC Market Access and Reimbursement

      15.1

      The United States

      15.2

      In EU4 and the UK

      15.3

      Japan

      15.4

      Summary and Comparison of Market Access and Pricing Policy Developments in 2025

      15.5

      Market Access and Reimbursement of PROTAC Therapies

      16

      Bibliography

      17

      PROTAC Market Report Methodology

      Related Reports

      Non-small Cell Lung Cancer Market

      Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including Daiichi Sankyo, AstraZeneca, Gilead Sciences, BieGene, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, BerGenBio, GlaxoSmithKline, Duality Biologics, and others.

      Metastatic Castration-Resistant Prostate Cancer Market

      Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mCRPC companies including Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others.

      Colorectal Cancer Market

      Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key colorectal cancer companies, including Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris, Biotherapeutics, and others.

      Metastatic HR+/HER2− Breast Cancer Market

      Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic HR+/HER2− breast cancer companies, including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, and others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur
      [email protected]
      +14699457679

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research LLP

      Modal title

      Also from this source

      Global Implanted Brain-Computer Interface Devices Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight

      Global Implanted Brain-Computer Interface Devices Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight

      DelveInsight's Implanted Brain-Computer Interface Devices Market Insights report provides the current and forecast market analysis, individual...

      Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight

      Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight

      DelveInsight's Rhabdomyosarcoma Market Insights report includes a comprehensive understanding of current treatment practices, rhabdomyosarcoma...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.